Wissenschaftliche Arbeiten

Uzm. Dr. Bengü Dursun

22 Publikationen. Neben jeder Publikation steht die Quelle der Angabe.

Zurück zum Profil

  1. Clinicopathological Correlates of High Stromal Tumor-infiltrating Lymphocytes in Luminal Breast Cancer: A Real-world Study

    Journal of Oncological Sciences, 2026

    DOI 10.37047/jos.galenos.2026.2026-3-11 Frei zugänglicher VolltextQuelle: OpenAlex

  2. Clinical Significance of Achieving No Evidence of Disease in HER2-Positive Metastatic Breast Cancer: A Multicenter Study by Turkish Oncology Group (TOG)

    Cancers, 2026

    DOI 10.3390/cancers18060915 PMID 41899520 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

  3. Prognostic Significance of the CPS-EG Score in Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy

    Cancers, 2026

    DOI 10.3390/cancers18142302 PMID 42512369 Frei zugänglicher VolltextQuelle: ORCID

  4. Does Timing Matter? Impact of Time to Surgery on Pathologic Response in Gastric Cancer Patients Treated with Perioperative FLOT

    Medicina, 2026

    DOI 10.3390/medicina62061080 PMID 42356093 Frei zugänglicher VolltextQuelle: OpenAlex

  5. Clinical Impact of Cytomegalovirus Infection in Patients with Inflammatory Bowel Disease

    Turkish Journal of Gastroenterology, 2026

    DOI 10.5152/tjg.2026.25407 PMID 41846476 Frei zugänglicher VolltextQuelle: ORCID

  6. Are Changes in PET/CT SUVmax Associated with Pathologic Complete Response in Breast Cancer Patients Receiving Neoadjuvant Therapy?

    Acta Haematologica Oncologica Turcica, 2026

    DOI 10.4274/ahot.galenos.2026.2026-2-6 Frei zugänglicher VolltextQuelle: ORCID

  7. Baseline vitamin D levels and progression-free survival in patients with HR+/HER2-metastatic breast cancer treated with ribociclib: a retrospective single-center analysis

    Discover Oncology, 2026

    DOI 10.1007/s12672-026-05502-2 PMID 42340556 Frei zugänglicher VolltextQuelle: ORCID

  8. Concordance Between ChatGPT and Real-World Adjuvant Chemotherapy Decisions in pT3N0 Colon Cancer

    Eurasian Journal of Medical Investigation, 2026

    DOI 10.14744/ejmi.2612508 Quelle: ORCID

  9. Real-world treatment compliance and outcomes in adult patients with localized Ewing sarcoma: A single-institution retrospective study

    Medicine, 2025

    DOI 10.1097/md.0000000000043405 PMID 40696651 Frei zugänglicher VolltextQuelle: OpenAlex

  10. TARE-Induced Pan-Immune Inflammation Value as a Prognostic Biomarker in Liver-Dominant Metastatic Colorectal Cancer

    Journal of Clinical Medicine, 2025

    DOI 10.3390/jcm14144927 PMID 40725620 3 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

  11. The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study

    International Journal of Clinical Oncology, 2024

    DOI 10.1007/s10147-023-02460-5 PMID 38310597 6 Zitationen (Europe PMC) Quelle: OpenAlex

  12. The impact of human epidermal growth factor receptor-2 (low) status on the efficacy of first line cyclin-dependent kinase 4/6 inhibitors in advanced breast cancer

    Medicine, 2024

    DOI 10.1097/md.0000000000038828 PMID 39058877 2 Zitationen (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

  13. Prolonged clinical response is possible with regorafenib in refractory osteosarcoma: A case report

    Journal of Clinical and Experimental Investigations, 2024

    DOI 10.29333/jcei/15645 Frei zugänglicher VolltextQuelle: ORCID

  14. The prognostic impact of Her2 status in early triple negative breast cancer: a Turkish Oncology Group (TOG) study

    Scientific Reports, 2024

    DOI 10.1038/s41598-024-75293-5 PMID 39384975 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

  15. Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group

    The Oncologist, 2023

    DOI 10.1093/oncolo/oyad257 PMID 37676712 8 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  16. The efficacy of immunotherapy and chemoimmunotherapy in patients with advanced rare tumors: A Turkish oncology group ( TOG ) study

    Cancer Medicine, 2023

    DOI 10.1002/cam4.6869 PMID 38140782 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  17. Comparison of Adjuvant Modified FOLFIRINOX with Other Adjuvant Chemotherapies in Resected Pancreatic Adenocarcinoma: Real-life Data

    Acta Oncologica Turcica, 2023

    DOI 10.5505/aot.2023.41196 Frei zugänglicher VolltextQuelle: OpenAlex

  18. 429P The impact of HER2 status on the efficacy of CDK 4/6 inhibitors: A multicenter study

    Annals of Oncology, 2023

    DOI 10.1016/j.annonc.2023.09.605 Frei zugänglicher VolltextQuelle: OpenAlex

  19. Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye

    Eurasian Journal of Medicine and Oncology, 2023

    DOI 10.14744/ejmo.2023.48337 1 Zitation (OpenAlex) Frei zugänglicher VolltextQuelle: ORCID

  20. Clinical outcomes of cyclin-dependent kinase 4–6 (CDK 4–6) inhibitors in patients with male breast cancer: A multicenter study

    Breast, 2022

    DOI 10.1016/j.breast.2022.09.009 PMID 36208540 16 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

  21. Seasonal Influenza and Pneumococcal Vaccination Rates Among Patients with Cancer in COVID-19 Pandemic: A Cross-Sectional Study

    Journal of Oncological Sciences, 2021

    DOI 10.37047/jos.2021-83087 2 Zitationen (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

  22. Clinical course of COVID-19 infection in elderly patient with melanoma on nivolumab

    Journal of Oncology Pharmacy Practice, 2020

    DOI 10.1177/1078155220924084 PMID 32423324 17 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID